Truist Securities Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $37
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsPrice Target
Truist Securities analyst Gregory Renza maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and lowers the price target from $39 to $37.
Truist Securities analyst Gregory Renza maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and lowers the price target from $39 to $37.